Replies to post #109383 on Biotech Values

[DewDiligence]

I predict VEGF-Trap-Eye will do less than $300M of peak annual sales in the US, where REGN owns the commercial rights. In the rest of the world, where there will be even more resistance to a premium-priced alternative to Avastin than in the US, I doubt that VEGF-Trap-Eye will do even that much.